Cathepsin K inhibitors as treatment of bone metastasis
Authors:
- Edith BonnelyeEBEdith Bonnelye
- Philippe ClézardinPCPhilippe Clézardin
- 1 September 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 2 (3) , 218-222
Abstract
Cancer cells that metastasize to the skeleton are, on their own, rarely able to destroy bone. Instead, they stimulate the function of bone-degrading cells, the osteoclasts, leading to the formation of osteolytic lesions. The purpose of this review is to consider cathepsin K, a cysteine protease produced by osteoclasts, as a therapeutic target for the treatment of patients with osteolytic bone metastases. Cathepsin K plays a key role in osteoclast-mediated bone degradation. It is also produced by cancer cells that metastasize to bone where it functions in proteolytic pathways that promote cancer cell invasion. Highly selective and potent cathepsin K inhibitors have been recently developed and shown to be useful antiresorptive agents to treat osteoporosis. Moreover, preclinical studies show that cathepsin K inhibitors reduce breast cancer-induced osteolysis and skeletal tumor burden. This reduction of skeletal tumor burden is due to the antiresorptive activity of cathepsin K inhibitors, which in turn, deprive cancer cells of bone-derived growth factors that are required for tumor growth. Cathepsin K inhibitors are appropriate drugs to treat diseases associated with increased bone loss. However, their chronic use in treating osteoporosis may result in adverse effects because basic nitrogen-containing cathepsin K inhibitors accumulate within acidic organelles such as lysosomes, thereby inhibiting the activity of other cathepsins. These adverse effects should not, however, preclude the use of these drugs in life-threatening diseases such as bone metastasis.Keywords
This publication has 23 references indexed in Scilit:
- Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental ArthritisScience, 2008
- Bone metastasis: pathogenesis and therapeutic implicationsClinical & Experimental Metastasis, 2007
- Cathepsin K Null Mice Show Reduced Adiposity during the Rapid Accumulation of Fat StoresPLOS ONE, 2007
- Cathepsin L activity controls adipogenesis and glucose toleranceNature Cell Biology, 2007
- Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug TargetsCurrent Pharmaceutical Design, 2007
- multifunctional enzymes in cancerNature Reviews Cancer, 2006
- Osteoclastic Bone Degradation and the Role of Different Cysteine Proteinases and Matrix Metalloproteinases: Differences Between Calvaria and Long BoneJournal of Bone and Mineral Research, 2006
- Accelerated Turnover of Metaphyseal Trabecular Bone in Mice Overexpressing Cathepsin KJournal of Bone and Mineral Research, 2001
- Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient miceProceedings of the National Academy of Sciences, 1998
- Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K DeficiencyScience, 1996